VARANASI: A landmark Indian study, \"Unveiling Oral Cancer’s Molecular Blueprint: A Novel Classification to Guide Precision ...
Computational pathology-informed immune biomarker for trastuzumab benefit in HER2+ breast cancer: Validation in NSABP B-41 clinical trial. Analysis of event-free survival (EFS) of stromal tumor ...
In a significant move aimed at strengthening regulatory clarity for cancer related medical technologies, the Central Drugs ...
Experts cited by reports stated that this regulation was crucial as it ensures that such emerging technologies are utilised ...
A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved their quality of life. By Gina Kolata Breast cancer patients whose tumors have ...